Borgeson John
Chief Financial Officer
Pharmaceutical Sciences
Alexo Therapeutics
Ireland
Biography
Mr. Borgeson’s prior experience includes over 20 years at Pfizer where he was a member of Pfizer’s Global Financial Leadership Team and held several financial positions of increasing responsibility. His most recent role at Pfizer was Vice President, Finance for Pfizer’s biotherapeutic research division where he had broad strategic, financial and operational responsibility over building Pfizer’s biotechnology franchise. Since leaving Pfizer in 2010, Mr. Borgeson has led finance for a variety of private companies, including Labrys Biologics, Solstice Biologics and Heart Metabolics. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Mr. Borgeson started his career at Ernst & Young and is a certified public accountant. He has an MBA from the Rochester Institute of Technology (RIT) and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.). Mr. Borgeson’s prior experience includes over 20 years at Pfizer where he was a member of Pfizer’s Global Financial Leadership Team and held several financial positions of increasing responsibility. His most recent role at Pfizer was Vice President, Finance for Pfizer’s biotherapeutic research division where he had broad strategic, financial and operational responsibility over building Pfizer’s biotechnology franchise. Since leaving Pfizer in 2010, Mr. Borgeson has led finance for a variety of private companies, including Labrys Biologics, Solstice Biologics and Heart Metabolics. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Mr. Borgeson started his career at Ernst & Young and is a certified public accountant. He has an MBA from the Rochester Institute of Technology (RIT) and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Research Interest
biotherapeutic research